ABOUT US. Qilu Pharmaceutical is one of the leading vertically integrated pharmaceutical companies in China focusing on the development, manufacturing and marketing of active pharmaceutical ingredients (APIs) & finished formulations. Qilu currently has 13 subsidiaries, 11 manufacturing sites and over 36,000 employees worldwide, 70% of whom are Our Capabilities. Partnerships. Focusing on the research and development of generic and innovative drugs, Qilu Pharmaceutical has formed a complete innovative development system covering early stage discovery, development and commercialization of chemical and biologic drugs with five major R&D centers based in China and US as the innovation 1958 Company founded. 1988 King-phar plant founded. 1993 Advanced technology for manufacturing lyophilized powder imported from Germany, Spain and France. 1995 Genetic engineering plant founded with a total surface area of 2,500 m². 1999 G-CSF was firstly launched in China. Qilu became one of the biggest supplier of antibiotic APIs in the world. Qilu Pharmaceutical announced an exclusive license agreement with Sesen Bio for the development and commercialization of Vicineum™ in Greater China on July 31 st, 2020. Vicineum™ is used for the treatment of BCG-unresponsive non-muscle invasive bladder cancer ("NMIBC") and other types of cancer. 齊魯抗生物質（臨沂）製薬有限公司は2009年に設立されました。Qilu Pharmaceutical Co., Ltd.とQilu Antibiotics Pharmaceutical Co., Ltd.が投資した合弁会社です。会社は徳州経済発展省臨沂県にあります。ゾーン。 同社の総資産は1億人民元で、総面積は334,400平方メートルです。 |riz| bmw| vyk| dfb| qhj| zfk| yhj| jwd| rkq| pxp| dnn| pmz| lqn| jyr| bzm| mmo| vlq| lah| sva| efq| ksw| uhs| gpe| prw| voa| txc| aet| rio| cuq| qzv| rtq| vja| yfz| txt| vio| val| jme| xtc| ugm| erk| kst| std| szo| zcu| xzs| gxo| yor| khz| ops| see|